Head and neck paragangliomas: Clinical and molecular genetic classification

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 19-28

  Offergeld, Christian ^a   Brase, Christoph ^b   Yaremchuk, Svetlana ^c   Mader, Irina ^d   Rischke, Hans Christian ^d   Gläsker, Sven ^d   Schmid, Kurt W ^e   Wiech, Thorsten ^d   Preuss, Simon F ^f   Suárez, Carlos ^g   Kopeć, Tomasz ^h   Patocs, Attila ⁱ   Wohllk, Nelson ^j   Malekpour, Mahdi ^k,l   Boedeker, Carsten C ^a   Neumann, Hartmut P H ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j UNIVERSITY OF CHILE   (Chile)

^k TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Fisch Classification; Paraganglioma; Shamblin Classification; Susceptibility Genes

Indexed keywords

CANCER STAGING; CAROTID BODY TUMOR; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; HUMAN; PARAGANGLIOMA; PATHOLOGY; REVIEW; SKULL BASE TUMOR; TUMOR GENE;

CAROTID BODY TUMOR; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PARAGANGLIOMA; SKULL BASE NEOPLASMS;

EID: 84863954540     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)05     Document Type: Review

References (75)

1. Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer. 2005;4(1):55-9, http://dx.doi.org/10.1007/s10689-004-2154-z.
2. Jackson CG, Glasscock ME, 3rd, Harris PF. Glomus Tumors. Diagnosis, classification, and management of large lesions. Arch Otolaryngol. 1982;108(7):401-10.
3. Kollert M, Minovi A, Mangold R, Hendus J, Draf W, Bockmuhl U. [Paraganglioma of the head and neck-tumor control, functional results and quality of life]. Laryngorhinootologie. 2006;85(9):649-56. Paragangliome des Kopf-Hals-Bereiches-Tumorkontrolle, funktionelle Ergebnisse und Lebensqualitat nach Operation.
4. Sykes JM, Ossoff RH. Paragangliomas of the head and neck. Otolaryngol Clin North Am. 1986;19(4):755-67.
5. Wasserman PG, Savargaonkar P. Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngol Clin North Am. 2001;34(5):845-62, vvi, http://dx.doi.org/10.1016/S0030-6665(05)70351-0.
6. Patetsios P, Gable DR, Garrett WV, Lamont JP, Kuhn JA, Shutze WP, et al. Management of carotid body paragangliomas and review of a 30-year experience. Ann Vasc Surg. 2002;16(3):331-8, http://dx.doi.org/10.1007/s10016-001-0106-8.
7. Persky MS, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A. Combined endovascular and surgical treatment of head and neck paragangliomasa team approach. Head Neck. 2002;24(5):423-31, http://dx.doi.org/10.1002/hed.10068.
8. Miller RB, Boon MS, Atkins JP, Lowry LD. Vagal paraganglioma: the Jefferson experience. Otolaryngol Head Neck Surg. 2000;122(4):482-7, http://dx.doi.org/10.1016/S0194-5998(00)70088-X.
9. Gehrking E, Gliemroth J, Missler U, Remmert S. [Main symptom: "pulsesynchronous tinnitus"]. Laryngorhinootologie. 2000;79(9):510-6. Hauptsymptom: "Pulssynchrones Ohrgerausch", http://dx.doi.org/10.1055/s-2000-6944.
10. Urquhart AC, Johnson JT, Myers EN, Schechter GL. Glomus vagale: paraganglioma of the vagus nerve. Laryngoscope. 1994;104(4):440-5.
11. Heinrich MC, Harris AE, Bell WR. Metastatic intravagal paraganglioma. Case report and review of the literature. Am J Med. 1985:78(6 Pt 1):1017-24, http://dx.doi.org/10.1016/0002-9343(85)90226-8.
12. Jackson CG. Glomus tympanicum and glomus jugulare tumors. Otolaryngol Clin North Am. 2001;34(5):941-70, vii, http://dx.doi.org/10.1016/S0030-6665(05)70356-X.
13. Rosenwasser H. Glomus jugulare tumors. I. Historical background. Arch Otolaryngol. 1968;88(1):1-40.
14. Boedeker CC. [Paragangliomas and paraganglioma syndromes]. Laryngorhinootologie. 2011;90(Suppl 1):S56-82. Paragangliome und Paragangliomsyndrome, http://dx.doi.org/10.1055/s-0030-1270447.
15. Alkadhi H, Schuknecht B, Stoeckli SJ, Valavanis A. Evaluation of topography and vascularization of cervical paragangliomas by magnetic resonance imaging and color duplex sonography. Neuroradiology. 2002;44(1):83-90.
16. Stoeckli SJ, Schuknecht B, Alkadhi H, Fisch U. Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography. Laryngoscope. 2002;112(1):143-6, http://dx.doi.org/10.1097/00005537-200201000-00025.
17. HR. H. Glomus Tympanicum Paraganglioma. In: Harnsberger HR, ed. Diagnostic Imaging Head and Neck Altona Manitoba, Canada. Amirsys Inc., Salt Lake City, UT, USA, I-2-82; I-82-83 2005.
18. van den Berg R. Imaging and management of head and neck paragangliomas. Eur Radiol. 2005;15(7):1310-8, http://dx.doi.org/10.1007/s00330-005-2743-8.
19. Christie A, Teasdale E. A comparative review of multidetector CT angiography and MRI in the diagnosis of jugular foramen lesions. Clin Radiol. 2010;65(3):213-7, http://dx.doi.org/10.1016/j.crad.2009.11.006.
20. Zeitler DM, Glick J, Har-El G. Preoperative embolization in carotid body tumor surgery: is it required? Ann Otol Rhinol Laryngol. 2010;119(5):279-83.
21. Kwekkeboom DJ, van Urk H, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993;34(6):873-8.
22. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. (68)Ga-DOTA-TATE PET vs. (123)I-MIBG in Identifying Malignant Neural Crest Tumours. Mol Imaging Biol. 2011;13(4): 769-75, http://dx.doi.org/10.1007/s11307-010-0396-8.
23. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8): 943-51, http://dx.doi.org/10.1001/jama.292.8.943.
24. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010;72(2):137-45, http://dx.doi.org/10.1111/j.1365-2265.2009.03648.x.
25. Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg. 1971;122(6):732-9, http://dx.doi.org/10.1016/0002-9610(71)90436-3.
26. Anand VK, Alemar GO, Sanders TS. Management of the internal carotid artery during carotid body tumor surgery. Laryngoscope. 1995;105 (3 Pt 1):231-5, http://dx.doi.org/10.1288/00005537-199503000-00001.
27. Fisch UMD. Microsurgery of the skull base. Stuttgart: Thieme; 1988.
28. Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005;294(16):2057-63, http://dx.doi.org/10.1001/jama.294.16.2057.
29. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268-70.
30. Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, et al. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer. 2010;18(1):73-83, http://dx.doi.org/10.1677/ERC-10-0113.
31. Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011-20, http://dx.doi.org/10.1093/hmg/ddq206.
32. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611-9, http://dx.doi.org/10.1001/jama.2010.1830.
33. Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab. 2011;96(8):E1279-82.
34. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77-85, http://dx.doi.org/10.1016/j.ccr.2004.11.022.
35. Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii N. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 2005;65(1):203-9.
36. Slane BG, Aykin-Burns N, Smith BJ, Kalen AL, Goswami PC, Domann FE, et al. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res. 2006;66(15):7615-20, http://dx.doi.org/10.1158/0008-5472.CAN-06-0833.
37. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69(8):3650-6, http://dx.doi.org/10.1158/0008-5472.CAN-08-4057.
38. Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2009;94(6):1938-44, http://dx.doi.org/10.1210/jc.2009-0354.
39. Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41-51, http://dx.doi.org/10.1002/humu.21136.
40. Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11(4):366-72, http://dx.doi.org/10.1016/S1470-2045(10)70007-3.
41. Foote RL, Pollock BE, Gorman DA, Schomberg PJ, Stafford SL, Link MJ, et al. Glomus jugulare tumor: tumor control and complications after stereotactic radiosurgery. Head Neck. 2002;24(4):332-8, http://dx.doi.org/10.1002/hed.10005.
42. Wang SJ, Wang MB, Barauskas TM, Calcaterra TC. Surgical management of carotid body tumors. Otolaryngol Head Neck Surg. 2000;123(3):202-6, http://dx.doi.org/10.1067/mhn.2000.106709.
43. Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Antonelli PJ, Cassisi NJ. Definitive radiotherapy in the management of chemodectomas arising in the temporal bone, carotid body, and glomus vagale. Head Neck. 2001;23(5):363-71, http://dx.doi.org/10.1002/hed.1045.
44. Hodge KM, Byers RM, Peters LJ. Paragangliomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1988;114(8):872-7, http://dx.doi.org/10.1001/archotol.1988.01860200056018.
45. Gstoettner W, Matula C, Hamzavi J, Kornfehl J, Czerny C. Long-term results of different treatment modalities in 37 patients with glomus jugulare tumors. Eur Arch Otorhinolaryngol. 1999;256(7):351-5, http://dx.doi.org/10.1007/s004050050162.
46. Biller HF, Lawson W, Som P, Rosenfeld R. Glomus vagale tumors. Ann Otol Rhinol Laryngol. 1989;98(1 Pt 1):21-6.
47. Thabet MH, Kotob H. Cervical paragangliomas: diagnosis, management and complications. J Laryngol Otol. 2001;115(6):467-74.
48. Schipper J, Spetzger U, Tatagiba M, Rosahl S, Neumann HP, Boedeker CC, et al. Juxtacondylar approach in temporal paraganglioma surgery: when and why? Skull Base. 2009;19(1):43-7, http://dx.doi.org/10.1055/s-0028-1103129.
49. Ivan ME, Sughrue ME, Clark AJ, Kane AJ, Aranda D, Barani IJ, et al. A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors. J Neurosurg. 2011;114(5):1299-305.
50. Powell S, Peters N, Harmer C. Chemodectoma of the head and neck: results of treatment in 84 patients. Int J Radiat Oncol Biol Phys. 1992;22(5):919-24.
51. Liu JK, Sameshima T, Gottfried ON, Couldwell WT, Fukushima T. The combined transmastoid retro-and infralabyrinthine transjugular transcondylar transtubercular high cervical approach for resection of glomus jugulare tumors. Neurosurgery. 2006;59(1 Suppl 1):ONS115-25.
52. Leonetti JP, Brackmann DE, Prass RL. Improved preservation of facial nerve function in the infratemporal approach to the skull base. Otolaryngol Head Neck Surg. 1989;101(1):74-8.
53. Schmid KW, Schroder S, Dockhorn-Dworniczak B, Kirchmair R, Totsch M, Bocker W, et al. Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretogranin II in extra-adrenal paragangliomas. Mod Pathol. 1994;7(3):347-53.
54. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551-66, http://dx.doi.org/10.1097/00000478-200205000-00002.
55. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10(8):764-71, http://dx.doi.org/10.1016/S1470-2045(09)70164-0.
56. Span PN, Rao JU, Oude Ophuis SB, Lenders JW, Sweep FC, Wesseling P, et al. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma. Endocr Relat Cancer. 2011;18(3):323-31, http://dx.doi.org/10.1530/ERC-10-0184.
57. Lim JY, Kim J, Kim SH, Lee S, Lim YC, Kim JW, et al. Surgical treatment of carotid body paragangliomas: outcomes and complications according to the shamblin classification. Clin Exp Otorhinolaryngol. 2010;3(2):91-5, http://dx.doi.org/10.3342/ceo.2010.3.2.91.
58. Plukker JT, Brongers EP, Vermey A, Krikke A, van den Dungen JJ. Outcome of surgical treatment for carotid body paraganglioma. Br J Surg. 2001;88(10):1382-6, http://dx.doi.org/10.1046/j.0007-1323. 2001.01878.x.
59. Makeieff M, Raingeard I, Alric P, Bonafe A, Guerrier B, Marty-Ane C. Surgical management of carotid body tumors. Ann Surg Oncol. 2008;15(8):2180-6, http://dx.doi.org/10.1245/s10434-008-9977-z.
60. Briner HR, Linder TE, Pauw B, Fisch U. Long-term results of surgery for temporal bone paragangliomas. Laryngoscope. 1999;109(4):577-83, http://dx.doi.org/10.1097/00005537-199904000-00011.
61. Huy PT, Kania R, Duet M, Dessard-Diana B, Mazeron JJ, Benhamed R. Evolving concepts in the management of jugular paraganglioma: a comparison of radiotherapy and surgery in 88 cases. Skull Base. 2009;19(1):83-91, http://dx.doi.org/10.1055/s-0028-1103125.
62. Sanna M, Jain Y, De Donato G, Rohit, Lauda L, Taibah A. Management of jugular paragangliomas: the Gruppo Otologico experience. Otol Neurotol. 2004;25(5):797-804, http://dx.doi.org/10.1097/00129492-2004 09000-00025.
63. Sanna M, Fois P, Pasanisi E, Russo A, Bacciu A. Middle ear and mastoid glomus tumors (glomus tympanicum): an algorithm for the surgical management. Auris Nasus Larynx. 2010;37(6):661-8, http://dx.doi.org/10.1016/j.anl.2010.03.006.
64. Fayad JN, Keles B, Brackmann DE. Jugular foramen tumors: clinical characteristics and treatment outcomes. Otol Neurotol. 2010;31(2):299-305, http://dx.doi.org/10.1097/MAO.0b013e3181be6495.
65. Miller JP, Semaan M, Einstein D, Megerian CA, Maciunas RJ. Staged Gamma Knife radiosurgery after tailored surgical resection: a novel treatment paradigm for glomus jugulare tumors. Stereotact Funct Neurosurg. 2009;87(1):31-6, http://dx.doi.org/10.1159/000195717.
66. Saringer W, Kitz K, Czerny C, Kornfehl J, Gstottner W, Matula C, et al. Paragangliomas of the temporal bone: results of different treatment modalities in 53 patients. Acta Neurochir (Wien). 2002;144(12):1255-64, http://dx.doi.org/10.1007/s00701-002-1016-4.
67. Cosetti M, Linstrom C, Alexiades G, Tessema B, Parisier S. Glomus tumors in patients of advanced age: a conservative approach. Laryngoscope. 2008;118(2):270-4, http://dx.doi.org/10.1097/MLG.0b013 e318158194b.
68. Durvasula VS, De R, Baguley DM, Moffat DA. Laser excision of glomus tympanicum tumours: long-term results. Eur Arch Otorhinolaryngol. 2005;262(4):325-7, http://dx.doi.org/10.1007/s00405-004-0822-0.
69. Papaspyrou K, Mann WJ, Amedee RG. Management of head and neck paragangliomas: review of 120 patients. Head Neck. 2009;31(3):381-7, http://dx.doi.org/10.1002/hed.20967.
70. Papaspyrou K, Mewes T, Toth M, Schmidtmann I, Amedee RG, Mann WJ. Hearing results after hypotympanotomy for glomus tympanicum tumors. Otol Neurotol. 2011;32(2):291-6, http://dx.doi.org/10.1097/MAO. 0b013e3182001edb.
71. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998;124(10):1133-40.
72. Zanoletti E, Mazzoni A. Vagal paraganglioma. Skull Base. 2006;16(3):161-7, http://dx.doi.org/10.1055/s-2006-949519.
73. Bausch B, Borozdin W, Neumann HP. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med. 2006;354(25):2729-31, http://dx.doi.org/10.1056/NEJMc066006.
74. Hensen EF, Bayley JP. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer. 2011;10(2):355-63, http://dx.doi.org/10.1007/s10689-010-9402-1.
75. Neumann HP, Eng C. The approach to the patient with paraganglioma. J Clin Endocrinol Metab. 2009;94(8):2677-83, http://dx.doi.org/10.1210/jc.2009-0496.